Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Migraine

Free Subscription Articles published in Cephalalgia Retrieve available abstracts of 238 articles: HTML format

Single Articles

September 2025
1. GOADSBY PJ, Ruiz de la Torre E, Maassen van den Brink A, Irimia P, et al
   Migraine stigma and general knowledge of migraine: A cross-sectional European survey.
   Cephalalgia. 2025;45:3331024251368251.
   PubMed     Abstract available
   
   
   
2. IFERGANE G
   Reinterpreting migraine in a societal evolutionary context.
   Cephalalgia. 2025;45:3331024251374315.
   PubMed    
   
   
   
3. MOSKOWITZ MA
   Rethinking migraine with aura: Why cortical spreading depolarization (depression), not aura, causes headaches.
   Cephalalgia. 2025;45:3331024251370629.
   PubMed     Abstract available
   
   
   
4. VIANA M, Peres MFP
   The spectrum of migraine aura: Towards a precise phenotypic classification.
   Cephalalgia. 2025;45:3331024251372621.
   PubMed     Abstract available
   
   
   
5. CASILLO F, Sebastianelli G, Abagnale C, Di Renzo A, et al
   Brain imaging in migraine with and without aura: Similarities and differences.
   Cephalalgia. 2025;45:3331024251365807.
   PubMed     Abstract available
   
   
   
6. ROMERO-REYES M, Akerman S, Rapoport AM
   Optimising combined treatment for migraine and temporomandibular disorders (TMDs).
   Cephalalgia. 2025;45:3331024251368882.
   PubMed     Abstract available
   
   
   
7. FERNANDES C, Gil-Gouveia R
   Deciphering the mechanisms: Pathophysiology of migraine-related cognitive dysfunction.
   Cephalalgia. 2025;45:3331024251368328.
   PubMed     Abstract available
   
   
   
8. PIETRA AD, Kuburas A, Russo AF
   PACAP versus CGRP in migraine: From mouse models to clinical translation.
   Cephalalgia. 2025;45:3331024251364242.
   PubMed     Abstract available
   
   
   
9. CLEMENTE L, Paparella G, Scannicchio S, Abbatantuono C, et al
   Dorso lateral prefrontal cortex stimulation with TMS in chronic migraine individuals refractory to anti-CGRP monoclonal antibodies: Clinical, neuropsychological and neurophysiological effects.
   Cephalalgia. 2025;45:3331024251364843.
   PubMed     Abstract available
   
   
   
10. ROBBLEE J, Khan FA, Marmura MJ, O'Brien HL, et al
    Reaching international consensus on the definition of refractory migraine using the Delphi method.
    Cephalalgia. 2025;45:3331024251367767.
    PubMed     Abstract available
    
    
    
11. BRACA S, Santoro V, Sebastianelli G, Schankin CJ, et al
    Visual snow vs. migraine aura: Debate summary and novel insights into the syndrome.
    Cephalalgia. 2025;45:3331024251365908.
    PubMed     Abstract available
    
    
    August 2025
12. ALPAY B, Christensen RH, Al-Khazali HM, Ashina M, et al
    Substance P and the trigeminovascular system: From preclinical mechanisms to human headache induction.
    Cephalalgia. 2025;45:3331024251355944.
    PubMed     Abstract available
    
    
    
13. VAGHI G, Corrado M, Pocora MM, Bighiani F, et al
    Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis.
    Cephalalgia. 2025;45:3331024251353421.
    PubMed     Abstract available
    
    
    
14. TASMA Z, Hay DL
    Decoding PACAP signaling: Splice variants, pathways and designer drugs.
    Cephalalgia. 2025;45:3331024251363560.
    PubMed     Abstract available
    
    
    
15. SACCO S
    The "Migraines" epidemic: Exposing the challenges of artificial intelligence in scientific writing.
    Cephalalgia. 2025;45:3331024251365833.
    PubMed    
    
    
    
16. VALENCA MM
    Proposal of a migraine with associated myofascial pain phenotype: Bridging corpalgia, fibromyalgia and chronic migraine.
    Cephalalgia. 2025;45:3331024251360223.
    PubMed    
    
    
    
17. VAN VEELEN N, Pelzer N, van der Arend BWH, Waslam N, et al
    The psychometric properties of an e-headache diary in migraine.
    Cephalalgia. 2025;45:3331024251359222.
    PubMed     Abstract available
    
    
    
18. CHRISTENSEN RH, Strassman AM, Ashina M, Ashina H, et al
    Opening of ATP-sensitive potassium channels activates meningeal nociceptors: Implications for the origin of migraine headache.
    Cephalalgia. 2025;45:3331024251359237.
    PubMed     Abstract available
    
    
    
19. DOMINGUEZ-MORENO R, Karlsson WK, Al-Khazali HM, Christensen RH, et al
    Plasma adrenomedullin levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251360234.
    PubMed     Abstract available
    
    
    
20. CHRISTENSEN RH, Al-Khazali HM, Ashina M, Vashchenko N, et al
    Differences in cortical morphometry between persistent post-traumatic headache, migraine and healthy controls.
    Cephalalgia. 2025;45:3331024251362830.
    PubMed     Abstract available
    
    
    
21. JOHNSON MP, Krikke-Workel J, Patel CN, Morin SM, et al
    Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.
    Cephalalgia. 2025;45:3331024251368757.
    PubMed     Abstract available
    
    
    
22. FERREIRA KDS, Velly AM
    Acute confusional migraine: Proposal for inclusion in the International Classification of Headache Disorders - 4th edition (ICHD-4).
    Cephalalgia. 2025;45:3331024251370305.
    PubMed    
    
    
    
23. ASHINA S, Ashina M, Holle-Lee D, Tassorelli C, et al
    Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.
    Cephalalgia. 2025;45:3331024251365206.
    PubMed     Abstract available
    
    
    
24. EDVINSSON L
    Is PACAP the next big thing in migraine therapy?
    Cephalalgia. 2025;45:3331024251368748.
    PubMed    
    
    
    
25. PELES I, Sharvit S, Steen YM, Gordon M, et al
    Invisible burdens: Gender-specific associations between migraine and work-family conflict: Insights from the SMILE project - a cohort study.
    Cephalalgia. 2025;45:3331024251352533.
    PubMed     Abstract available
    
    
    
26. RUSSO A, Silvestro M, Finkelstein I, Seabi D, et al
    Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence.
    Cephalalgia. 2025;45:3331024251370608.
    PubMed     Abstract available
    
    
    
27. THURAIAIYAH J, Christensen RH, Al-Khazali HM, Wiggers A, et al
    Overlap between perceived triggers, premonitory symptoms and symptom persistence across migraine phases: A REFORM study.
    Cephalalgia. 2025;45:3331024251364234.
    PubMed     Abstract available
    
    
    
28. ZHAI Q, Li H, Chen Q, Zhang N, et al
    Microglial TRPV2-mediated neuroinflammation promotes central sensitization through microglial polarization in a vestibular migraine mouse model.
    Cephalalgia. 2025;45:3331024251364753.
    PubMed     Abstract available
    
    
    July 2025
29. CHAN NJ, Chen YY, Hsu CC, Lin YS, et al
    Sensitizing effect of antimigraine drug sumatriptan on capsaicin-sensitive lung vagal neurons via 5-HT(1B/1D) receptors and PKA: Relevance to adverse chest effects.
    Cephalalgia. 2025;45:3331024251355949.
    PubMed     Abstract available
    
    
    
30. ROMOZZI M, Scipioni L, Di Tella S, Silveri MC, et al
    Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.
    Cephalalgia. 2025;45:3331024251314460.
    PubMed     Abstract available
    
    
    
31. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey-matter network topology in migraine with aura.
    Cephalalgia. 2025;45:3331024251353146.
    PubMed     Abstract available
    
    
    
32. NIELSEN BS, Wang H, Ramdal Techlo T, Kogelman L, et al
    Genome sequencing reveals the Adgrl3 (ADGRL3) gene as a possible cause of cephalic hypersensitivity in the STA rat and migraine in humans.
    Cephalalgia. 2025;45:3331024251352844.
    PubMed     Abstract available
    
    
    
33. HU YY, Mei HR, Sankar S, Pirwani A, et al
    Post-stress modulation of the HPA and melanocortin systems alleviates migraine-like behaviors in mice.
    Cephalalgia. 2025;45:3331024251352856.
    PubMed     Abstract available
    
    
    
34. AILANI J, Pavlovic J, Pixton GC, Fullerton T, et al
    Rimegepant safety and patient-reported outcomes among triptan-naive, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study.
    Cephalalgia. 2025;45:3331024251343309.
    PubMed     Abstract available
    
    
    
35. ZHUANG ZA, Al-Karagholi MA, Ashina H, Do TP, et al
    Effect of sumatriptan on ATP-sensitive potassium channel opening in migraine: A randomised controlled trial.
    Cephalalgia. 2025;45:3331024251341464.
    PubMed     Abstract available
    
    
    
36. ANDREOU AP, Iannone LF
    The ongoing pursuit of migraine triggering mechanisms.
    Cephalalgia. 2025;45:3331024251342583.
    PubMed    
    
    
    
37. VILLAR-MARTINEZ MD, Goadsby PJ
    Cranial autonomic symptoms as a protective mechanism in patients with chronic migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251359564.
    PubMed     Abstract available
    
    
    
38. BOTTIROLI S, Cangelosi M, Allena M, Icco R, et al
    Childhood traumas delineate a distinct psychological and clinical profile in adults with migraine: The hidden burden.
    Cephalalgia. 2025;45:3331024251358503.
    PubMed     Abstract available
    
    
    
39. BOCZARSKA-JEDYNAK M, Blumenfeld AM
    When should the effectiveness of a botulinum toxin A for chronic migraine be assessed in the face of newest International Headache Society recommendations?
    Cephalalgia. 2025;45:3331024251363268.
    PubMed    
    
    
    
40. ALSAADI T, Suliman R, Yang J, Agarwal E, et al
    A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.
    Cephalalgia. 2025;45:3331024251355947.
    PubMed     Abstract available
    
    
    
41. PETRUSIC I
    Digital phenotyping for migraine: A game-changer for research and management.
    Cephalalgia. 2025;45:3331024251363568.
    PubMed     Abstract available
    
    
    
42. SUZUKI Y, Kiyosawa M
    Characteristics of visual snow syndrome in Japan and its association with migraine.
    Cephalalgia. 2025;45:3331024251360337.
    PubMed     Abstract available
    
    
    
43. TEPPER SJ, Jenkins A, Henriksen C, Dai F, et al
    A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data.
    Cephalalgia. 2025;45:3331024251352849.
    PubMed     Abstract available
    
    
    June 2025
44. CHAUDHRY BA, Younis S, Messina R, Garcia-Azorin D, et al
    Cortical thickness studies in migraine: Current evidence and future directions.
    Cephalalgia. 2025;45:3331024251341204.
    PubMed     Abstract available
    
    
    
45. SILVESTRO M, Orologio I, Sozio P, Dortucci V, et al
    No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies.
    Cephalalgia. 2025;45:3331024251329808.
    PubMed     Abstract available
    
    
    
46. JAIMES A, Rodriguez-Vico J, Pajares O, Eguilior Caffarena I, et al
    Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study.
    Cephalalgia. 2025;45:3331024251346925.
    PubMed     Abstract available
    
    
    
47. ASHINA S, Kim G, Muenzel EJ, Buse DC, et al
    Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study.
    Cephalalgia. 2025;45:3331024251341243.
    PubMed     Abstract available
    
    
    
48. WENNERSTEN T, Lindh JD, Nilsson Remahl AIM, Andersson ML, et al
    Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: A nested case-control study.
    Cephalalgia. 2025;45:3331024251348648.
    PubMed     Abstract available
    
    
    
49. LING YH, Pan LH, Chen SP, Chen WT, et al
    Comorbidity with fibromyalgia predicted poorer outcomes in patients with chronic migraine on flunarizine: Prospective proof-of-concept study.
    Cephalalgia. 2025;45:3331024251353412.
    PubMed     Abstract available
    
    
    May 2025
50. WONG HT, Khan R, Buture A, Khalil M, et al
    OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull.
    Cephalalgia. 2025;45:3331024251327387.
    PubMed     Abstract available
    
    
    
51. EMMENEGGER MJ, Gantenbein AR
    Philosophical aspects of migraine: Headache treatment is a human-to-human service.
    Cephalalgia. 2025;45:3331024251343225.
    PubMed     Abstract available
    
    
    
52. SORRENTINO A, Di Lorenzo C
    Comment on: Setting higher standards for migraine prevention: A position statement of the International Headache Society.
    Cephalalgia. 2025;45:3331024251343217.
    PubMed    
    
    
    
53. GOZALOV E, Karlsson WK, Christensen RH, Al-Khazali HM, et al
    Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251338178.
    PubMed     Abstract available
    
    
    
54. PORRECA F, Navratilova E, Dodick DW
    Advancing understanding of migraine pathophysiology and therapy by consideration of patient sex.
    Cephalalgia. 2025;45:3331024251339466.
    PubMed     Abstract available
    
    
    
55. MORENO-AJONA D, Gosalia H, Hoffmann J, Goadsby PJ, et al
    Amylin and the amylin receptors in migraine: Is there another pathway to target?
    Cephalalgia. 2025;45:3331024251340066.
    PubMed     Abstract available
    
    
    
56. RUSSO A, Reuter U
    Raising the bar in migraine prevention: Toward freedom and optimal control.
    Cephalalgia. 2025;45:3331024251331198.
    PubMed    
    
    
    
57. ORNELLO R, D'Atri A, De Icco R, De Santis F, et al
    Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC): Results of a randomized controlled trial.
    Cephalalgia. 2025;45:3331024251325567.
    PubMed     Abstract available
    
    
    
58. GOLLION C, Ashina H, Hackert Christensen R, Al-Khazali HM, et al
    Intact white matter in adults with migraine: A REFORM MRI study.
    Cephalalgia. 2025;45:3331024251339423.
    PubMed     Abstract available
    
    
    April 2025
59. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    Reply to "What is the evolutionary disadvantage of migraine?".
    Cephalalgia. 2025;45:3331024251327377.
    PubMed    
    
    
    
60. LISICKI M, Schoenen J
    What is the evolutionary disadvantage of migraine?
    Cephalalgia. 2025;45:3331024251327361.
    PubMed    
    
    
    
61. MAS-DE-LES-VALLS R, Gomez-Dabo L, Caronna E, Gallardo VJ, et al
    Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days.
    Cephalalgia. 2025;45:3331024251332519.
    PubMed     Abstract available
    
    
    
62. VALENCA MM, Szewczyk AK
    Stroke-like migraine attacks after radiation therapy (SMART) syndrome: A call for standardized diagnostic criteria.
    Cephalalgia. 2025;45:3331024251334355.
    PubMed    
    
    
    
63. ROBBLEE J
    Rethinking status migrainosus: Escalation shouldn't wait for 72 hours.
    Cephalalgia. 2025;45:3331024251334137.
    PubMed    
    
    
    
64. VERNIERI F, Iannone LF, Lo Castro F, Sebastianelli G, et al
    Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).
    Cephalalgia. 2025;45:3331024251335927.
    PubMed     Abstract available
    
    
    
65. HAGHDOOST F
    Internet and social media's role in migraine education: Headache or not headache?
    Cephalalgia. 2025;45:3331024251336152.
    PubMed    
    
    
    
66. AL-KHAZALI HM, Christensen RH, Ashina H
    Clinical comparisons between post-traumatic headache and migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251331605.
    PubMed     Abstract available
    
    
    
67. GONZALEZ-MARTINEZ A, Wei DY, Karsan N, Nagaraj K, et al
    Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine.
    Cephalalgia. 2025;45:3331024251331554.
    PubMed     Abstract available
    
    
    
68. MESSINA R, Chong CD
    Migraine and the white matter microstructure controversy: Time for a methodological reset?
    Cephalalgia. 2025;45:3331024251339431.
    PubMed    
    
    
    
69. SEBASTIANELLI G
    The 'theory of everything' for migraine pathophysiology will never exist: Insights from glial cells.
    Cephalalgia. 2025;45:3331024251338171.
    PubMed    
    
    
    
70. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
    Evidence-based guidelines for the pharmacological treatment of migraine, summary version.
    Cephalalgia. 2025;45:3331024251321500.
    PubMed     Abstract available
    
    
    
71. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
    Evidence-based guidelines for the pharmacological treatment of migraine.
    Cephalalgia. 2025;45:3331024241305381.
    PubMed     Abstract available
    
    
    March 2025
72. OMLAND PM, Hansen JO, Neverdahl JP, Mykland MS, et al
    Migraine and insufficient sleep: The effect of sleep restriction on nociceptive evoked potentials in migraine.
    Cephalalgia. 2025;45:3331024251329400.
    PubMed     Abstract available
    
    
    
73. PULEDDA F, Tassorelli C
    Reply to "Reassessing partial efficacy or not responding to acute migraine treatment".
    Cephalalgia. 2025;45:3331024251325543.
    PubMed    
    
    
    
74. POZO-ROSICH P, van Veelen N, Caronna E, Vaghi G, et al
    Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache.
    Cephalalgia. 2025;45:3331024251318016.
    PubMed     Abstract available
    
    
    
75. YANG L, Jin T, Wang H
    Reassessing partial efficacy or not responding to acute migraine treatment.
    Cephalalgia. 2025;45:3331024251325526.
    PubMed    
    
    
    
76. BAI Y, Chu MK, Kang JJ, Chae J, et al
    No change in interictal plasma and salivary CGRP levels in individuals with vestibular migraine corresponding to episodic migraine.
    Cephalalgia. 2025;45:3331024251322418.
    PubMed     Abstract available
    
    
    February 2025
77. GUZMAN G, Kopruszinski CM, Barber KR, Lillo Vizin RC, et al
    Chronification of migraine sensitizes to CGRP in male and female mice.
    Cephalalgia. 2025;45:3331024251317446.
    PubMed     Abstract available
    
    
    
78. CHEEMA S, Lagrata S, Rantell KR, Ahmed M, et al
    OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine.
    Cephalalgia. 2025;45:3331024251317448.
    PubMed     Abstract available
    
    
    
79. GANTENBEIN AR
    Depression screening in migraine - A double-edged sword.
    Cephalalgia. 2025;45:3331024251317606.
    PubMed    
    
    
    
80. GOADSBY PJ, Jurgens TP, Brand-Schieber E, Nagy K, et al
    Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.
    Cephalalgia. 2025;45:3331024251320610.
    PubMed     Abstract available
    
    
    
81. SACCO S, Ashina M, Diener HC, Haghdoost F, et al
    Setting higher standards for migraine prevention: A position statement of the International Headache Society.
    Cephalalgia. 2025;45:3331024251320608.
    PubMed     Abstract available
    
    
    
82. ASHEER J, Ali F, Hilker R, Videbech P, et al
    Methodological challenges in using screening tools for depression in migraine: A systematic review.
    Cephalalgia. 2025;45:3331024251317635.
    PubMed     Abstract available
    
    
    
83. SZABO E, Bolo NR, Borsook D, Burstein R, et al
    Peripherally acting anti-CGRP monoclonal antibodies attenuate cortical resting-state connectivity in migraine patients.
    Cephalalgia. 2025;45:3331024241313377.
    PubMed     Abstract available
    
    
    
84. LIAO YH, Tzeng YS, Chen SP, Ling YH, et al
    Association between headache frequency and risk for fibromyalgia in patients with migraine.
    Cephalalgia. 2025;45:3331024251317486.
    PubMed     Abstract available
    
    
    
85. ZORRILLA E, Krivoshein G, Kuburas A, Schenke M, et al
    Combined effects of cannabidiol and Delta9-tetrahydrocannabinol alleviate migraine-like symptoms in mice.
    Cephalalgia. 2025;45:3331024251314487.
    PubMed     Abstract available
    
    
    January 2025
86. STAEHR C, Nyegaard M, Bach FW, Rohde PD, et al
    Exploring the association between familial hemiplegic migraine genes (CACNA1A, ATP1A2 and SCN1A) with migraine and epilepsy: A UK Biobank exome-wide association study.
    Cephalalgia. 2025;45:3331024241306103.
    PubMed     Abstract available
    
    
    
87. MOHAMMAD S, Bussu G, Rukh G, Schioth HB, et al
    Migraine and its major subtypes - with and without aura are associated with polygenic scores for autism.
    Cephalalgia. 2025;45:3331024241312666.
    PubMed     Abstract available
    
    
    
88. LEE GJ, Hode V, Georgieva T, Rau J, et al
    Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis.
    Cephalalgia. 2025;45:3331024241313378.
    PubMed     Abstract available
    
    
    
89. VAN DER AREND BWH, van Welie FC, Olsen MH, Versijpt J, et al
    Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications.
    Cephalalgia. 2025;45:3331024241297673.
    PubMed     Abstract available
    
    
    December 2024
90. GENDOLLA A, Brown JD, Mercadante AR, Drakeley S, et al
    The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey.
    Cephalalgia. 2024;44:3331024241276415.
    PubMed     Abstract available
    
    
    
91. 
    Abstracts of the 20(th) Biennial Migraine Trust International Symposium, London UK, 5th to 8th September 2024.
    Cephalalgia. 2024;44:3331024241280496.
    PubMed    
    
    
    
92. OLESEN J, Tfelt-Hansen P
    Methodology of drug trials in migraine: History and suggestions for the future.
    Cephalalgia. 2024;44:3331024241298642.
    PubMed     Abstract available
    
    
    
93. ROMOZZI M, Lokhandwala A, Vollono C, Vigani G, et al
    An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine.
    Cephalalgia. 2024;44:3331024241262751.
    PubMed     Abstract available
    
    
    
94. PETERLIN BL, Bond DS, Ailani J, Dodick DW, et al
    Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.
    Cephalalgia. 2024;44:3331024241299753.
    PubMed     Abstract available
    
    
    
95. GOTTSCHALK C, Gandhi P, Pozo-Rosich P, Christie S, et al
    Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.
    Cephalalgia. 2024;44:3331024241300305.
    PubMed     Abstract available
    
    
    November 2024
96. BURGALASSI A, Romozzi M, Vigani G, De Icco R, et al
    Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.
    Cephalalgia. 2024;44:3331024241273968.
    PubMed     Abstract available
    
    
    
97. SACCO S, De Santis F, Onofri A, Rosignoli C, et al
    A call for academic pragmatic clinical trials to address open questions in migraine prevention.
    Cephalalgia. 2024;44:3331024241291574.
    PubMed     Abstract available
    
    
    
98. CLOET F, Gueyraud G, Lerebours F, Munio M, et al
    Stroke due to small-vessel disease and migraine: A case-control study of a young adult with ischemic stroke population.
    Cephalalgia. 2024;44:3331024241282015.
    PubMed     Abstract available
    
    
    
99. AILANI J, Lalla A, Halker Singh RB, Holle-Lee D, et al
    Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.
    Cephalalgia. 2024;44:3331024241299377.
    PubMed     Abstract available
    
    
    
100. PULEDDA F, de Boer I, Messina R, Garcia-Azorin D, et al
     Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.
     Cephalalgia. 2024;44:3331024241297688.
     PubMed     Abstract available
     
     
     
101. YANG C, Wei C, Alam S, Chen X, et al
     The neurotrophic factor artemin and its receptor GFRalpha3 mediate migraine-like pain via the ion channel TRPM8.
     Cephalalgia. 2024;44:3331024241297679.
     PubMed     Abstract available
     
     
     
102. DALLA VOLTA G, Russo A, Silvestro M, Ornello R, et al
     Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.
     Cephalalgia. 2024;44:3331024241299453.
     PubMed     Abstract available
     
     
     October 2024
103. SEBASTIANELLI G, Atalar AC, Cetta I, Farham F, et al
     Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis.
     Cephalalgia. 2024;44:3331024241287224.
     PubMed     Abstract available
     
     
     
104. PELES I, Sharvit S, Zlotnik Y, Gordon M, et al
     Migraine and work - beyond absenteeism: Migraine severity and occupational burnout - A cohort study.
     Cephalalgia. 2024;44:3331024241289930.
     PubMed     Abstract available
     
     
     
105. CAMMAROTA F, De Icco R, Vaghi G, Corrado M, et al
     High-frequency episodic migraine: Time for its recognition as a migraine subtype?
     Cephalalgia. 2024;44:3331024241291578.
     PubMed     Abstract available
     
     
     
106. TRILLER P, Blessing VN, Overeem LH, Fitzek MP, et al
     Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study.
     Cephalalgia. 2024;44:3331024241288875.
     PubMed     Abstract available
     
     
     September 2024
107. ACARSOY C, Ikram MK, Ikram MA, Vernooij MW, et al
     Migraine and brain structure in the elderly: The Rotterdam Study.
     Cephalalgia. 2024;44:3331024241266951.
     PubMed     Abstract available
     
     
     
108. KOPRUSZINSKI CM, Lee G, Martin LK, Barber KR, et al
     A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache.
     Cephalalgia. 2024;44:3331024241281493.
     PubMed     Abstract available
     
     
     
109. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
     International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine.
     Cephalalgia. 2024;44:3331024241269735.
     PubMed    
     
     
     
110. IHARA K, Casillo F, Dahshan A, Genc H, et al
     Are we closer to achieving precision medicine for migraine treatment? A narrative review.
     Cephalalgia. 2024;44:3331024241281518.
     PubMed     Abstract available
     
     
     
111. MELO-CARRILLO A, Strassman AM, Malcolm KJ, Adams AM, et al
     Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats.
     Cephalalgia. 2024;44:3331024241278919.
     PubMed     Abstract available
     
     
     
112. WILCHA RJ, Goadsby PJ
     Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study.
     Cephalalgia. 2024;44:3331024241278911.
     PubMed     Abstract available
     
     
     
113. CASILLO F, Di Renzo A, Sebastianelli G, Abagnale C, et al
     Lack of a direct link between macular cones function and photophobia in interictal migraine.
     Cephalalgia. 2024;44:3331024241276501.
     PubMed     Abstract available
     
     
     
114. ASHINA M, Steiner TJ, Hansen JM, Hauberg DS, et al
     Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021.
     Cephalalgia. 2024;44:3331024241269758.
     PubMed     Abstract available
     
     
     
115. ERNSTSEN C, Obelitz-Ryom K, Kristensen DMB, Olesen J, et al
     Mechanisms of GTN-induced migraine: Role of NOS isoforms, sGC and peroxynitrite in a migraine relevant mouse model.
     Cephalalgia. 2024;44:3331024241277542.
     PubMed     Abstract available
     
     
     
116. ELOSUA-BAYES I, Alpuente A, Melgarejo L, Caronna E, et al
     Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data.
     Cephalalgia. 2024;44:3331024241273966.
     PubMed     Abstract available
     
     
     August 2024
117. DO TP
     Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications.
     Cephalalgia. 2024;44:3331024241268058.
     PubMed    
     
     
     
118. OMLAND PM
     Enhanced learning in migraine: False positive finding or discovery of a new migraine trait?
     Cephalalgia. 2024;44:3331024241268297.
     PubMed    
     
     
     
119. STUBBERUD A, Borkenhagen S, Oteiza F, Dueland AN, et al
     Patterns of migraine medication use in Norway: A nationwide registry-based observational study.
     Cephalalgia. 2024;44:3331024241268212.
     PubMed     Abstract available
     
     
     
120. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
     International Headache Society global practice recommendations for the acute pharmacological treatment of migraine.
     Cephalalgia. 2024;44:3331024241252666.
     PubMed     Abstract available
     
     
     
121. KATSARAVA Z, Buse DC, Leroux E, Lanteri-Minet M, et al
     Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study.
     Cephalalgia. 2024;44:3331024241274343.
     PubMed     Abstract available
     
     
     
122. SIMMONDS L, Jamtoy KA, Aschehoug I, Hara S, et al
     Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.
     Cephalalgia. 2024;44:3331024241273967.
     PubMed     Abstract available
     
     
     
123. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
     Effects of levcromakalim in patients with migraine aura without headache: An experimental study.
     Cephalalgia. 2024;44:3331024241274366.
     PubMed     Abstract available
     
     
     
124. HU YY, Souza R, Muthuraman A, Knapp L, et al
     Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.
     Cephalalgia. 2024;44:3331024241277941.
     PubMed     Abstract available
     
     
     
125. MULLIN K, Croop R, Mosher L, Fullerton T, et al
     Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
     Cephalalgia. 2024;44:3331024241259456.
     PubMed     Abstract available
     
     
     
126. AL-KHAZALI HM, Al-Sayegh Z, Younis S, Christensen RH, et al
     Systematic review and meta-analysis of Neck Disability Index and Numeric Pain Rating Scale in patients with migraine and tension-type headache.
     Cephalalgia. 2024;44:3331024241274266.
     PubMed     Abstract available
     
     
     
127. PERES MFP, Sacco S, Pozo-Rosich P, Tassorelli C, et al
     Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action.
     Cephalalgia. 2024;44:3331024241267309.
     PubMed     Abstract available
     
     
     July 2024
128. RUSCHEWEYH R, Forderreuther S, Freilinger T, Gaul C, et al
     Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry.
     Cephalalgia. 2024 Jul 21:3331024241261077. doi: 10.1177/03331024241261077.
     PubMed     Abstract available
     
     
     
129. DE VRIES T, Boucherie DM, Chan KY, Rubio-Beltran E, et al
     Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine.
     Cephalalgia. 2024;44:3331024241254088.
     PubMed     Abstract available
     
     
     
130. TOT K, Braunitzer G, Harcsa-Pinter N, Kiss A, et al
     Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding.
     Cephalalgia. 2024;44:3331024241258722.
     PubMed     Abstract available
     
     
     June 2024
131. EXACOUSTOS C, Martire FG, Albanese M, Selntigia A, et al
     REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results.
     Cephalalgia. 2024;44:3331024241254821.
     PubMed    
     
     
     
132. LIU L, Chen Q, Zhao L, Lyu T, et al
     Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.
     Cephalalgia. 2024;44:3331024241261080.
     PubMed     Abstract available
     
     
     
133. ISHII R, Ishizuchi K, Watanabe N, Fukazawa R, et al
     Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
     Cephalalgia. 2024;44:3331024241258695.
     PubMed     Abstract available
     
     
     
134. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
     Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.
     Cephalalgia. 2024;44:3331024241258734.
     PubMed     Abstract available
     
     
     
135. RAFFAELLI B, Do TP, Ashina H, Snellman J, et al
     Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.
     Cephalalgia. 2024;44:3331024241259489.
     PubMed     Abstract available
     
     
     
136. LI H, Xu X, Xu R, Fan PX, et al
     Latent class analysis of migraine associated vestibular-auditory symptoms.
     Cephalalgia. 2024;44:3331024241262488.
     PubMed     Abstract available
     
     
     
137. BRAILLON A
     Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures.
     Cephalalgia. 2024;44:3331024241262486.
     PubMed    
     
     
     
138. 
     Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials".
     Cephalalgia. 2024;44:3331024241255216.
     PubMed    
     
     
     
139. 
     Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
     Cephalalgia. 2024;44:3331024241254952.
     PubMed    
     
     
     May 2024
140. RASMUSSEN AV, Jensen RH, Gantenbein A, Sumelahti ML, et al
     Consensus recommendations on the role of nurses in headache care: A European e-Delphi study.
     Cephalalgia. 2024;44:3331024241252161.
     PubMed     Abstract available
     
     
     
141. KOKOTI L, Al-Karagholi MA, Zhuang ZA, Amirguliyev S, et al
     Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: A randomized clinical trial.
     Cephalalgia. 2024;44:3331024241248211.
     PubMed     Abstract available
     
     
     
142. AKGOR U, Ince O
     Comment on ''Correlation between endometriosis and migraine features: Results from a prospective case-control study''.
     Cephalalgia. 2024;44:3331024241254824.
     PubMed    
     
     
     
143. GIRI S, Tronvik E, Dalen H, Ellekjaer H, et al
     Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trondelag Health Study.
     Cephalalgia. 2024;44:3331024241254517.
     PubMed     Abstract available
     
     
     
144. AL-HASSANY L, Boucherie DM, Couturier EGM, MaassenVanDenBrink A, et al
     Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
     Cephalalgia. 2024;44:3331024241248837.
     PubMed     Abstract available
     
     
     April 2024
145. RATTANAWONG W, Rapoport A, Srikiatkhachorn A
     Medication "underuse" headache.
     Cephalalgia. 2024;44:3331024241245658.
     PubMed     Abstract available
     
     
     
146. MITTER VR, Lupattelli A, Bjork MH, Nordeng HME, et al
     Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study.
     Cephalalgia. 2024;44:3331024241248846.
     PubMed     Abstract available
     
     
     
147. GARCIA-AZORIN D, Martinez-Badillo C, Camina Muniz J, Gago-Veiga AB, et al
     CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
     Cephalalgia. 2024;44:3331024241248833.
     PubMed     Abstract available
     
     
     
148. WHITAKER DJ, Dumkrieger GM, Hentz JG, Dodick DW, et al
     Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.
     Cephalalgia. 2024;44:3331024241249747.
     PubMed     Abstract available
     
     
     
149. CROOP R, Berman G, Kudrow D, Mullin K, et al
     A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
     Cephalalgia. 2024;44:3331024241232944.
     PubMed     Abstract available
     
     
     
150. OLFAT M, Hosseinpour S, Masoumi S, Gogia Rastogi R, et al
     A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial.
     Cephalalgia. 2024;44:3331024241230963.
     PubMed     Abstract available
     
     
     March 2024
151. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
     Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
     Cephalalgia. 2024;44:3331024241233979.
     PubMed     Abstract available
     
     
     
152. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
     Correlation between endometriosis and migraine features: Results from a prospective case-control study.
     Cephalalgia. 2024;44:3331024241235210.
     PubMed     Abstract available
     
     
     
153. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
     Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
     Cephalalgia. 2024;44:3331024241238153.
     PubMed     Abstract available
     
     
     
154. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
     Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
     Cephalalgia. 2024;44:3331024241237247.
     PubMed     Abstract available
     
     
     
155. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
     Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
     Cephalalgia. 2024;44:3331024231226181.
     PubMed     Abstract available
     
     
     
156. SACCO S, Porreca F
     Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
     Cephalalgia. 2024;44:3331024241238157.
     PubMed    
     
     
     
157. DIENER HC, May A
     New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication.
     Cephalalgia. 2024;44:3331024241228605.
     PubMed     Abstract available
     
     
     
158. ASHINA H, Diener HC, Tassorelli C, Scher AI, et al
     Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.
     Cephalalgia. 2024;44:3331024241234068.
     PubMed     Abstract available
     
     
     February 2024
159. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
     Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
     Cephalalgia. 2024;44:3331024231222923.
     PubMed     Abstract available
     
     
     
160. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
     Premonitory symptoms in migraine: A REFORM Study.
     Cephalalgia. 2024;44:3331024231223979.
     PubMed     Abstract available
     
     
     
161. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
     How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
     Cephalalgia. 2024;44:3331024241229410.
     PubMed     Abstract available
     
     
     
162. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
     Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
     Cephalalgia. 2024;44:3331024241234809.
     PubMed     Abstract available
     
     
     
163. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
     Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
     Cephalalgia. 2024;44:3331024241230279.
     PubMed     Abstract available
     
     
     
164. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
     Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
     Cephalalgia. 2024;44:3331024241235156.
     PubMed     Abstract available
     
     
     
165. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
     Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
     Cephalalgia. 2024;44:3331024241235139.
     PubMed     Abstract available
     
     
     January 2024
166. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
     Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
     Cephalalgia. 2024;44:3331024231225186.
     PubMed    
     
     
     
167. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
     Systemic allergic reaction to galcanezumab (emgality): a case report.
     Cephalalgia. 2024;44:3331024231222914.
     PubMed     Abstract available
     
     
     
168. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
     Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
     Cephalalgia. 2024;44:3331024231222637.
     PubMed     Abstract available
     
     
     
169. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
     Cumulative exposure to estrogen may increase the risk of migraine in women.
     Cephalalgia. 2024;44:3331024231225972.
     PubMed     Abstract available
     
     
     
170. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
     No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
     Cephalalgia. 2024;44:3331024231222915.
     PubMed     Abstract available
     
     
     
171. RAHMAN SM, Luebke AE
     Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
     Cephalalgia. 2024;44:3331024231223971.
     PubMed     Abstract available
     
     
     
172. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
     Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
     Cephalalgia. 2024;44:3331024231222916.
     PubMed     Abstract available
     
     
     
173. MONTE G, Papetti L, Ursitti F, Sforza G, et al
     Childhood primary stabbing headache: A double center study.
     Cephalalgia. 2024;44:3331024231225974.
     PubMed     Abstract available
     
     
     
174. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
     The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
     Cephalalgia. 2024;44:3331024231226323.
     PubMed     Abstract available
     
     
     December 2023
175. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
     Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
     Cephalalgia. 2023;43:3331024231218392.
     PubMed     Abstract available
     
     
     
176. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
     The evolutionary meaning of migraine.
     Cephalalgia. 2023;43:3331024231209303.
     PubMed     Abstract available
     
     
     
177. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
     Systemic lupus erythematosus mimicking retinal migraine: a case report.
     Cephalalgia. 2023;43:3331024231219477.
     PubMed     Abstract available
     
     
     
178. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
     Microstructural differences in migraine: A diffusion-tensor imaging study.
     Cephalalgia. 2023;43:3331024231216456.
     PubMed     Abstract available
     
     
     
179. AL-KARAGHOLI MA
     Targeting CGRP pathways and aura: A peripheral site with a central effect.
     Cephalalgia. 2023;43:3331024231212895.
     PubMed     Abstract available
     
     
     
180. CHRISTOPHERSEN P, Dyhring T
     The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
     Cephalalgia. 2023;43:3331024231219475.
     PubMed     Abstract available
     
     
     November 2023
181. VAN DER AREND B, Terwindt GM
     Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
     Cephalalgia. 2023;43:3331024231208123.
     PubMed    
     
     
     
182. DAUNGSUPAWONG H, Wiwanitkit V
     Comment on "Effect of COVID vaccination on monthly migraine days".
     Cephalalgia. 2023;43:3331024231208121.
     PubMed    
     
     
     
183. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
     Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
     Cephalalgia. 2023;43:3331024231210930.
     PubMed     Abstract available
     
     
     
184. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
     Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
     Cephalalgia. 2023;43:3331024231202243.
     PubMed     Abstract available
     
     
     
185. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
     Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
     Cephalalgia. 2023;43:3331024231212574.
     PubMed     Abstract available
     
     
     
186. BAHRA A
     Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
     Cephalalgia. 2023;43:3331024231214239.
     PubMed     Abstract available
     
     
     
187. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
     InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
     Cephalalgia. 2023;43:3331024231212900.
     PubMed     Abstract available
     
     
     
188. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
     Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
     Cephalalgia. 2023;43:3331024231214987.
     PubMed     Abstract available
     
     
     October 2023
189. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
     Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
     Cephalalgia. 2023;43:3331024231202240.
     PubMed     Abstract available
     
     
     
190. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
     An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
     Cephalalgia. 2023;43:3331024231206375.
     PubMed     Abstract available
     
     
     
191. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
     The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
     Cephalalgia. 2023;43:3331024231182684.
     PubMed     Abstract available
     
     
     
192. CHUANG CH, Li JY, King JT, Chen WT, et al
     Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
     Cephalalgia. 2023;43:3331024231206781.
     PubMed     Abstract available
     
     
     
193. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
     What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
     Cephalalgia. 2023;43:3331024231206376.
     PubMed     Abstract available
     
     
     
194. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
     Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
     Cephalalgia. 2023;43:3331024231208110.
     PubMed     Abstract available
     
     
     
195. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
     Body mass index and migraine in adolescence: A nationwide study.
     Cephalalgia. 2023;43:3331024231209309.
     PubMed     Abstract available
     
     
     
196. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
     Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
     Cephalalgia. 2023;43:3331024231206162.
     PubMed     Abstract available
     
     
     
197. BELIN AC, Barloese MC
     The genetics and chronobiology of cluster headache.
     Cephalalgia. 2023;43:3331024231208126.
     PubMed     Abstract available
     
     
     September 2023
198. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
     Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
     Cephalalgia. 2023;43:3331024231198792.
     PubMed     Abstract available
     
     
     August 2023
199. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
     Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
     Cephalalgia. 2023;43:3331024231177636.
     PubMed     Abstract available
     
     
     
200. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
     Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
     Cephalalgia. 2023;43:3331024231189751.
     PubMed     Abstract available
     
     
     
201. ADAM I, Elmugabil A, AlHabardi N
     History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
     Cephalalgia. 2023;43:3000605231193823.
     PubMed     Abstract available
     
     
     
202. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
     Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
     Cephalalgia. 2023;43:3331024231195780.
     PubMed     Abstract available
     
     
     
203. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
     Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
     Cephalalgia. 2023;51:3331024231190296.
     PubMed     Abstract available
     
     
     July 2023
204. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
     Symptoms associated with headache in youth.
     Cephalalgia. 2023;43:3331024231187162.
     PubMed     Abstract available
     
     
     June 2023
205. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
     Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
     Cephalalgia. 2023;43:3331024231164322.
     PubMed     Abstract available
     
     
     
206. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
     Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
     Cephalalgia. 2023;43:3331024231180564.
     PubMed     Abstract available
     
     
     
207. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
     Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
     Cephalalgia. 2023;43:3331024231178237.
     PubMed     Abstract available
     
     
     
208. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
     A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
     Cephalalgia. 2023;43:3331024231179131.
     PubMed     Abstract available
     
     
     
209. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
     Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
     Cephalalgia. 2023;43:3331024231182126.
     PubMed     Abstract available
     
     
     
210. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
     Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
     Cephalalgia. 2023;43:3331024231180611.
     PubMed     Abstract available
     
     
     
211. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
     The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231183166.
     PubMed     Abstract available
     
     
     
212. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
     Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
     Cephalalgia. 2023;43:3331024231170541.
     PubMed     Abstract available
     
     
     
213. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
     The prevalence and burden of medication overuse headache in Greece.
     Cephalalgia. 2023;43:3331024231184909.
     PubMed     Abstract available
     
     
     May 2023
214. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
     Defining migraine days, based on longitudinal E-diary data.
     Cephalalgia. 2023;43:3331024231166625.
     PubMed     Abstract available
     
     
     
215. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
     New daily persistent headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231168089.
     PubMed     Abstract available
     
     
     
216. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
     Forecasting migraine with machine learning based on mobile phone diary and wearable data.
     Cephalalgia. 2023;43:3331024231169244.
     PubMed     Abstract available
     
     
     
217. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
     Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
     Cephalalgia. 2023;43:3331024231170807.
     PubMed     Abstract available
     
     
     
218. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
     Characterizing opioid use in a Dutch cohort with migraine.
     Cephalalgia. 2023;43:3331024231174160.
     PubMed     Abstract available
     
     
     
219. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
     Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
     Cephalalgia. 2023;43:3331024231176074.
     PubMed     Abstract available
     
     
     
220. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
     Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
     Cephalalgia. 2023;43:3331024231170810.
     PubMed     Abstract available
     
     
     
221. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
     What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
     Cephalalgia. 2023;43:3331024231174855.
     PubMed     Abstract available
     
     
     
222. STEINER TJ
     Classification of migraine and tension-type headache: A response to the proposals of Olesen.
     Cephalalgia. 2023;43:3331024231169240.
     PubMed    
     
     
     
223. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
     Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
     Cephalalgia. 2023;43:3331024231177649.
     PubMed     Abstract available
     
     
     
224. PARK CG, Na HY, Park DE, Kim HY, et al
     Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
     Cephalalgia. 2023;43:3331024231178218.
     PubMed     Abstract available
     
     
     
225. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
     Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
     Cephalalgia. 2023;43:3331024231178239.
     PubMed     Abstract available
     
     
     April 2023
226. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
     Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231156922.
     PubMed     Abstract available
     
     
     
227. OLESEN J, Jensen RH
     The Global Campaign Against Headache and its future relation to IHS and WHO.
     Cephalalgia. 2023;43:3331024231159625.
     PubMed     Abstract available
     
     
     
228. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
     Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
     Cephalalgia. 2023;43:3331024231159366.
     PubMed     Abstract available
     
     
     
229. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
     An altered reward system characterizes chronic migraine with medication overuse headache.
     Cephalalgia. 2023;43:3331024231158088.
     PubMed     Abstract available
     
     
     
230. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
     "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
     Cephalalgia. 2023;43:3331024231161261.
     PubMed     Abstract available
     
     
     
231. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
     Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
     Cephalalgia. 2023;43:3331024231160519.
     PubMed     Abstract available
     
     
     
232. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
     Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
     Cephalalgia. 2023;43:3331024231157677.
     PubMed     Abstract available
     
     
     
233. ASHINA M, Roos C, Li LQ, Komori M, et al
     Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
     Cephalalgia. 2023;43:3331024231161745.
     PubMed     Abstract available
     
     
     
234. ZHANG L, Zhou Y, Wang Y, Yang L, et al
     Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
     Cephalalgia. 2023;43:3331024231163131.
     PubMed     Abstract available
     
     
     
235. RUSSO CV, Sacca F, Braca S, Sansone M, et al
     Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
     Cephalalgia. 2023;43:3331024231161809.
     PubMed     Abstract available
     
     
     
236. OLESEN J
     Classification of migraine and tension-type headache.
     Cephalalgia. 2023;43:3331024221139238.
     PubMed    
     
     
     
237. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
     Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
     Cephalalgia. 2023;43:3331024231161746.
     PubMed     Abstract available
     
     
     
238. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
     Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
     Cephalalgia. 2023;43:3331024231165682.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.